Acute Viral Rhinosinusitis Treatment Market (Treatment: Saline Nasal Spray, Nasal Corticosteroids, Decongestants, NSAIDs, and Others; Route of Administration: Topical, Nasal, Oral, and Injectable; Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies; and Infection Type: Rhinovirus [Picornavirus] and Non-Rhinovirus)- Global Industry Analysis, Share, Growth, Regional Outlook And Forecasts, 2021-2027

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global  Acute Viral Rhinosinusitis Treatment Market, By Treatment

7.1.   Acute Viral Rhinosinusitis Treatment  Market, by Treatment, 2021-2027

7.1.1.     Saline Nasal Spray

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Nasal Corticosteroids

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Fluticasone

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     Budesonide

7.1.4.1.          Market Revenue and Forecast (2016-2027)

7.1.5.     Mometasone

7.1.5.1.          Market Revenue and Forecast (2016-2027)

7.1.6.     Others

7.1.6.1.          Market Revenue and Forecast (2016-2027)

7.1.7.     Decongestants

7.1.7.1.          Market Revenue and Forecast (2016-2027)

7.1.8.     Topical Decongestants

7.1.8.1.          Market Revenue and Forecast (2016-2027)

7.1.9.     Systemic Decongestants

7.1.9.1.          Market Revenue and Forecast (2016-2027)

7.1.10.  NSAIDs

7.1.10.1.       Market Revenue and Forecast (2016-2027)

7.1.11.  Acetaminophen

7.1.11.1.       Market Revenue and Forecast (2016-2027)

7.1.12.  Ibuprofen

7.1.12.1.       Market Revenue and Forecast (2016-2027)

7.1.13.  Aspirin

7.1.13.1.       Market Revenue and Forecast (2016-2027)

7.1.14.  Others

7.1.14.1.       Market Revenue and Forecast (2016-2027)

Chapter 8.    Global  Acute Viral Rhinosinusitis Treatment Market, By Route of Administration

8.1.   Acute Viral Rhinosinusitis Treatment  Market, by Route of Administration, 2021-2027

8.1.1.     Topical

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Nasal

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Oral

8.1.3.1.          Market Revenue and Forecast (2016-2027)

8.1.4.     Injectable

8.1.4.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global  Acute Viral Rhinosinusitis Treatment Market, By Distribution Channel

9.1.   Acute Viral Rhinosinusitis Treatment  Market, by Distribution Channel, 2021-2027

9.1.1.     Online Pharmacies

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Retail Pharmacies

9.1.2.1.          Market Revenue and Forecast (2016-2027)

9.1.3.     Hospital Pharmacies

9.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global  Acute Viral Rhinosinusitis Treatment Market, By Infection Type

10.1.           Acute Viral Rhinosinusitis Treatment  Market, by Infection Type, 2021-2027

10.1.1.  Rhinovirus (Picornavirus)

10.1.1.1.       Market Revenue and Forecast (2016-2027)

10.1.2.  Non-Rhinovirus

10.1.2.1.       Market Revenue and Forecast (2016-2027)

10.1.3.  Influenza

10.1.3.1.       Market Revenue and Forecast (2016-2027)

10.1.4.  Enterovirus

10.1.4.1.       Market Revenue and Forecast (2016-2027)

10.1.5.  Adenovirus

10.1.5.1.       Market Revenue and Forecast (2016-2027)

10.1.6.  Others

10.1.6.1.       Market Revenue and Forecast (2016-2027)

Chapter 11.Global  Acute Viral Rhinosinusitis Treatment  Market, Regional Estimates and Trend Forecast

11.1.          North America

11.1.1.  Market Revenue and Forecast, by Treatment (2016-2027)

11.1.2.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.1.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.1.4.  Market Revenue and Forecast, by Infection Type (2016-2027)

11.1.5.  U.S.

11.1.5.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.1.5.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.1.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.1.5.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.1.6.  Rest of North America

11.1.6.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.1.6.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.1.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.1.6.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.2.          Europe

11.2.1.  Market Revenue and Forecast, by Treatment (2016-2027)

11.2.2.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.2.4.  Market Revenue and Forecast, by Infection Type (2016-2027)

11.2.5.  UK

11.2.5.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.2.5.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.2.5.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.2.6.  Germany

11.2.6.1.       Market Revenue and Forecast, by Treatment(2016-2027)

11.2.6.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.2.6.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.2.7.  France

11.2.7.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.2.7.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.2.7.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.2.8.  Rest of Europe

11.2.8.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.2.8.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.8.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.2.8.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.3.          APAC

11.3.1.  Market Revenue and Forecast, by Treatment (2016-2027)

11.3.2.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.3.4.  Market Revenue and Forecast, by Infection Type (2016-2027)

11.3.5.  India

11.3.5.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.3.5.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.3.5.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.3.6.  China

11.3.6.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.3.6.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.3.6.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.3.7.  Japan

11.3.7.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.3.7.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.3.7.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.3.8.  Rest of APAC

11.3.8.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.3.8.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.8.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.3.8.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.4.          MEA

11.4.1.  Market Revenue and Forecast, by Treatment (2016-2027)

11.4.2.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.4.4.  Market Revenue and Forecast, by Infection Type (2016-2027)

11.4.5.  GCC

11.4.5.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.4.5.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.4.5.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.4.6.  North Africa

11.4.6.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.4.6.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.4.6.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.4.7.  South Africa

11.4.7.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.4.7.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.4.7.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.4.8.  Rest of MEA

11.4.8.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.4.8.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.8.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.4.8.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.5.          Latin America

11.5.1.  Market Revenue and Forecast, by Treatment (2016-2027)

11.5.2.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.5.4.  Market Revenue and Forecast, by Infection Type (2016-2027)

11.5.5.  Brazil

11.5.5.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.5.5.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.5.5.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

11.5.6.  Rest of LATAM

11.5.6.1.       Market Revenue and Forecast, by Treatment (2016-2027)

11.5.6.2.       Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

11.5.6.4.       Market Revenue and Forecast, by Infection Type (2016-2027)

Chapter 12.   Company Profiles

12.1.                 Sun Pharmaceutical Industries, Inc.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.                 Sun Pharmaceutical Industries, Inc.

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.                 Janssen Pharmaceuticals, Inc.

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.                 Fresenius Kabi USA

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.                 LLC

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.                 Dr. Reddy's Laboratories, Inc

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.                 Novartis AG

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.                 Teva Pharmaceutical Industries Ltd.

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.                 Sanofi

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.              Abbott Laboratories

12.10.1.                   Company Overview

12.10.2.                   Product Offerings

12.10.3.                   Financial Performance

12.10.4.                   Recent Initiatives

Chapter 13.   Research Methodology

13.1.                 Primary Research

13.2.                 Secondary Research

13.3.                 Assumptions

Chapter 14.   Appendix

14.1.                 About Us

14.2.                 Glossary of Terms